title: The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy.
abstract: OBJECTIVE
  Dual antiplatelet therapy is recommended after acute coronary syndrome or after percutaneous coronary intervention with coronary stent implantation. Many of the patients on dual antiplatelet therapy receive β-blockers; some of them could have antiaggregatory effect. Bisoprolol is a highly selective adrenoceptor-blocker, which is often used in the settings of percutaneous coronary intervention or acute coronary syndrome in patients on dual antiplatelet therapy. Its antiaggregative effect has not been extensively studied. Therefore, the aim of this study is to investigate the effect of bisoprolol on ADP-induced platelet aggregation in patients on dual antiplatelet therapy.
  
  
  METHODS
  Platelet aggregability has been measured in 100 patients on dual antiplatelet therapy with multiplate analyzer using ADP test in blood samples anticoagulated with heparin. ADP test values have been expressed by arbitrary units/minute. In univariate and multivariate regression analyses, we have investigated the influence of bisoprolol and its dose and also different factors, such as risk factors, concomitant drugs and their dosage, laboratory findings, on ADP test values.
  
  
  RESULTS
  Univariate regression analysis showed significant correlation between the bisoprolol dose and the ADP test value (P=0.046, B=52.55, 95% confidence interval 0.87-104.23), which was also shown in the multivariate regression analysis (P=0.018; B=57.011; 95% confidence interval 10.455-103.567).
  
  
  CONCLUSIONS
  We have identified a positive correlation between bisoprolol dose and ADP-induced platelet aggregability in patients on dual antiplatelet therapy.
authors.affiliation: Clinical Center Kragujevac, Zmaj Jovina, Serbia. vladaig@yahoo.com
authors.forename: Vladimir Slavisa
authors.initials: VS
authors.lastname: Ignjatovic
authors.forename: Njegos
authors.initials: N
authors.lastname: Petrovic
authors.forename: Vladimir
authors.initials: V
authors.lastname: Miloradovic
authors.forename: Snezana
authors.initials: S
authors.lastname: Ignjatovic
authors.forename: Vesna
authors.initials: V
authors.lastname: Cokanovic
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Grdinic
authors.forename: Ivan
authors.initials: I
authors.lastname: Simic
authors.forename: Ivica
authors.initials: I
authors.lastname: Petrovic
authors.forename: Sara
authors.initials: S
authors.lastname: Nikolic
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Andjelkovic
authors.forename: Dusan
authors.initials: D
authors.lastname: Paramentic
authors.forename: Slavisa
authors.initials: S
authors.lastname: Ignjatovic
mesh_terms: D000244:Adenosine Diphosphate; D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation; D017298:Bisoprolol / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012044:Regression Analysis; D018570:Risk Assessment; D012307:Risk Factors; D055771:Serbia; D015607:Stents
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D017298:Bisoprolol